China Approves Phase-I Trials for New mRNA Tumor Vaccine Targeting Epstein-Barr Virus
China’s WestGene Biopharma receives approval for Phase-I clinical trials of a pioneering mRNA vaccine targeting Epstein-Barr virus positive tumors, marking a significant breakthrough in cancer treatment.